DTG50mg+3TC300mg+TDF300mg tabs/PAC-30

Dolutegravir 50mg + Lamivudine 300mg + Tenofovir 300mg tablets in a bottle pack of 30 without or without outer carton
Indicative Price : Upon Request
Disclaimer: The images shown are for illustration purposes only and may not be an exact representation of the product. “No Generic Photo Available" means that there is not an image available for this product.

General description:
Dolutegravir 50mg + Lamivudine 300mg + Tenofovir disoproxil fumarate 300mg tablets in a bottle pack of 30 with or without outer carton. This product also comes in other pack sizes (90s, 180s).

Technical specifications:
Each tablet contains Dolutegravir 50mg + Lamivudine 300mg + Tenofovir disoproxil fumarate 300mg which is equivalent to 245mg of Tenofovir Disoproxil as fixed dose combination (FDC).

Therapeutic class:
Dolutegravir is an Integrase Inhibitor
Lamivudine is a Nucleoside Reverse Transcriptase Inhibitors (NRTI).
Tenofovir is a Nucleotide Reverse Transcriptase Inhibitor (NtRTI)

Management of HIV infection in children and adults. Administration by mouth (oral), PO.

Dosage, Instructions for use:
Please refer to the guideline WHO Model Formulary 2008:
http://apps.who.int/iris/bitstream/handle/10665/44053/9789241547659_eng. pdf?sequence=1
For more details, please see WHO treatment guidelines https://www.who.int/publications/i/item/9789240031593 and WHO Essential Medicines Library https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.02 or your regional/national guidelines.

Shelf life:
24 months

Storage and transportation:
Do not store above 30ºC, protect from light.
Store in tightly closed original container.
Keep out of reach and sight of children.

Component of a Kit:
This item is a component of S9901023 - IEHK2017, PEP kit (S1400652 - DTG50mg+3TC300mg+TDF300mg tabs/PAC-30 gb)

Alternative products:
The product may also be available in other formulations, pack sizes, or in combinations with other ARVs

Related Products